Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Nature Medicine2017Vol. 23(9), pp. 1046–1054
Citations Over TimeTop 10% of 2017 papers
Hana Janoušková, Geniver El Tekle, Elisa Bellini, Namrata D. Udeshi, Anna Maria Rinaldi, Anna Ulbricht, Tiziano Bernasocchi, Gianluca Civenni, Marco Losa, Tanya Svinkina, Craig M. Bielski, Gregory V. Kryukov, Luciano Cascione, Sara Napoli, Radoslav I. Enchev, David G. Mutch, Michael E. Carney, Andrew Berchuck, Boris Winterhoff, Russell R. Broaddus, Peter Schraml, Holger Moch, Francesco Bertoni, Carlo V. Catapano, Matthias Peter, Steven A. Carr, Levi A. Garraway, Peter J. Wild, Jean‐Philippe Theurillat
Related Papers
- → Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants(2023)15 cited
- → Missense mutations and the magnitude of functional deficit: the example of factor IX(1992)19 cited
- → Regional missense constraint improves variant deleteriousness prediction(2017)391 cited
- → Abstract P2-02-03: Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes(2017)
- → Evaluation of cancer related missense mutations in CENPH(2019)